

Probing into structural and functional features  
of the MHC-encoded peptide transporter TAP  
using herpesviral inhibitors

Dissertation zur Erlangung des akademischen Grades  
des Doktors der Naturwissenschaften (Dr. rer. nat.)

eingereicht im Fachbereich Biologie, Chemie, Pharmazie  
der Freien Universität Berlin

vorgelegt von  
Anne Halenius  
aus Pargas, Finnland

Mai, 2005

1. Gutachter: Prof. Dr. Hartmut Hengel, Heinrich-Heine-Universität Düsseldorf
2. Gutachter: Prof. Dr. Rupert Mutzel, Freie Universität Berlin

Disputation am 01.07.2005

**TABLE OF CONTENTS**

**ABBREVIATIONS ..... IV**

**SUMMARY ..... VI**

**ZUSAMMENFASSUNG ..... VIII**

**1 INTRODUCTION ..... 1**

1.1 THE MHC CLASS I ANTIGEN PRESENTING PATHWAY ..... 1

    1.1.1 *Protein degradation – antigen generation* ..... 2

    1.1.2 *Trimming peptidases* ..... 3

    1.1.3 *Peptide translocation and loading of peptides onto MHC I molecules*..... 3

1.2 THE HUMAN CYTOMEGALOVIRUS, HCMV ..... 6

    1.2.1 *HCMV inhibitors of the MHC class I antigen presenting pathway*..... 7

1.3 THE TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING, TAP ..... 10

    1.3.1 *TAP is an ABC transporter* ..... 10

    1.3.2 *Structure and function of TAP*..... 12

1.4 VIRAL TAP INHIBITORS ..... 16

    1.4.1 *gpUS6*..... 16

    1.4.2 *ICP47* ..... 17

    1.4.3 *Further viral TAP inhibitors* ..... 18

1.5 AIM OF THE STUDY ..... 19

**2 MATERIALS ..... 20**

2.1 DEVICES ..... 20

2.2 BIOCHEMICALS AND CHEMICALS ..... 21

2.3 KITS ..... 22

2.4 SOLUTIONS ..... 22

2.5 OLIGONUCLEOTIDES ..... 26

2.6 ANTIBODIES ..... 26

2.7 CELL LINES ..... 27

2.8 VIRUSES..... 28

**3 EXPERIMENTAL PROCEDURES ..... 29**

3.1 *E. COLI* PROTOCOLS ..... 29

    3.1.1 *Bacterial culture*..... 29

    3.1.2 *Storing of bacterial cultures*..... 29

    3.1.3 *Preparation of competent bacteria*..... 29

    3.1.4 *Transformation of DNA to competent E. coli*..... 29

3.2 DNA PROTOCOLS ..... 30

    3.2.1 *DNA preparation*..... 30

TABLE OF CONTENTS

---

3.2.2	<i>Cleaving and isolation of DNA fragments</i> .....	30
3.2.3	<i>Dephosphorylation of DNA fragments</i> .....	30
3.2.4	<i>Ligation of DNA fragments</i> .....	31
3.2.5	<i>PCR (polymerase chain reaction)</i> .....	31
3.2.6	<i>DNA sequencing</i> .....	32
3.2.7	<i>Construction of US6 and TAP mutants</i> .....	32
3.3	CELL CULTURE .....	33
3.4	WORKING WITH VACCINIA VIRUS.....	33
3.4.1	<i>Vaccinia virus stock</i> .....	33
3.4.2	<i>Titration of VV stock</i> .....	34
3.4.3	<i>VV infection for analysis</i> .....	34
3.5	RECOMBINANT VACCINIA VIRUS.....	34
3.5.1	<i>Preparation of VV DNA</i> .....	34
3.5.2	<i>Preparation of rVV</i> .....	35
3.5.3	<i>Isolation of VV DNA for PCR analysis</i> .....	37
3.5.4	<i>Sequencing of the p7.5k131a insert</i> .....	37
3.5.5	<i>Human and rat specific TAP primers</i> .....	38
3.6	PURIFICATION OF ANTIBODIES .....	38
3.7	QUANTIFICATION OF TOTAL PROTEIN.....	40
3.8	IMMUNO METHODS .....	40
3.8.1	<i>RIPA lysate</i> .....	40
3.8.2	<i>Denaturing SDS-PAGE</i> .....	40
3.8.3	<i>SDS-PAGE, nonreducing conditions</i> .....	41
3.8.4	<i>Blotting</i> .....	41
3.8.5	<i>Immunodetection</i> .....	41
3.8.6	<i>Immunoprecipitation of non-labeled proteins</i> .....	42
3.8.7	<i>Immunoprecipitation of metabolically labeled proteins</i> .....	42
3.8.8	<i>Endoglycosidase H cleaving of high mannose structures</i> .....	43
3.8.9	<i>Big scale SDS-PAGE</i> .....	44
3.8.10	<i>FACS</i> .....	45
3.9	PEPTIDE TRANSLOCATION ASSAY.....	45
3.10	ATP BINDING ASSAY .....	47
<b>4</b>	<b>RESULTS</b> .....	<b>49</b>
4.1	PREPARING CONDITIONS FOR CO-IMMUNOPRECIPITATION AND EXPRESSION OF A SOLUBLE GPUS6....	49
4.1.1	<i>Testing of anti-gpUS6 polyclonal rabbit antisera</i> .....	49
4.1.2	<i>Expression of gpUS6sol</i> .....	52
4.2	GPUS6 SPECIES-SPECIFICITY .....	54
4.2.1	<i>Inactivation of TAP by gpUS6 is species-restricted</i> .....	54
4.2.2	<i>gpUS6 binding to both TAP subunits is required for efficient inactivation of peptide transport..</i>	55
4.3	PROBING THE TAP1 TMD BY GPUS6.....	59
4.3.1	<i>The TAP1 C-terminal TMD contains a binding site for gpUS6</i> .....	59

## TABLE OF CONTENTS

4.3.2	<i>A soluble gpUS6 recognizes r8hT1, implying a TAP1 topology with 10 TMS</i> .....	62
4.3.3	<i>The predicted fifth luminal loop of TAP1 is not responsible for the inhibitory effect of gpUS6...</i>	64
4.4	GPUS6 INTERACTION WITH TAP2.....	67
4.4.1	<i>Inhibition of TAP2 by gpUS6 is directed by the C-terminal TMD</i> .....	68
4.4.2	<i>The gpUS6 binding domain on TAP2 localizes to the N-terminal TMD</i> .....	69
4.5	OLIGOMERIZATION OF GPUS6.....	72
4.6	ANALYSIS OF WALKER A TAP MUTANTS FOR GPUS6 RECOGNITION OF THE TAP TMD.....	74
4.6.1	<i>ATP binding to TAP2 induces conformational changes of the luminal TMD.....</i> <i>recognized by gpUS6.....</i>	74
4.6.2	<i>gpUS6 binding to TAP1 inhibits binding of ATP to the TAP1 NBD.....</i>	77
4.7	BINDING ANALYSIS OF ICP47 TO TAP.....	79
4.7.1	<i>ICP47 binding to TAP is absolutely dependent on TAP2, but not sufficient for functional</i> <i>inhibition.....</i>	79
4.7.2	<i>ICP47 recognition of TAP2 is dependent on at least two independent domains.....</i>	81
4.8	ICP47 RECOGNIZES AN ATP-INDEPENDENT CONFORMATION OF TAP.....	84
4.9	TAP BINDING BY ICP47 AND GPUS6 IS MUTUALLY EXCLUSIVE.....	85
<b>5</b>	<b>DISCUSSION.....</b>	<b>87</b>
5.1	DETERMINATION OF MINIMAL BINDING DOMAINS ON TAP FOR GPUS6 AND ICP47 USING HUMAN/RAT TAP CHIMERAS.....	87
5.1.1	<i>The membrane topology of TAP as determined by gpUS6.....</i>	88
5.1.2	<i>gpUS6 interference with TAP2.....</i>	90
5.1.3	<i>Model for gpUS6 inhibition and binding.....</i>	91
5.1.4	<i>Structural requirements of gpUS6.....</i>	93
5.1.5	<i>ICP47 interaction with TAP.....</i>	94
5.2	COMPARING CONFORMATIONAL REQUIREMENTS ON TAP FOR GPUS6 AND ICP47 RECOGNITION.....	97
5.2.1	<i>ATP binding to TAP2 is a prerequisite for gpUS6 recognition of TAP.....</i>	97
5.2.2	<i>ICP47 dependency on TAP conformation is insensitive to ATP binding and hydrolysis.....</i>	98
5.2.3	<i>gpUS6 and ICP47 interaction to TAP is mutually exclusive.....</i>	98
5.3	INTEGRATION OF GPUS6 AND ICP47 INTO A MODEL OF THE TAP TRANSLOCATION CYCLE.....	100
5.4	PERSPECTIVES.....	102
<b>6</b>	<b>APPENDIX I.....</b>	<b>103</b>
6.1	VALUATION OF A PUTATIVE TAP TRANSMEMBRANE TOPOLOGY.....	103
<b>7</b>	<b>REFERENCES.....</b>	<b>106</b>
<b>8</b>	<b>ACKNOWLEDGEMENTS.....</b>	<b>119</b>
	<b>PUBLICATIONS.....</b>	<b>121</b>
	<b>CURRICULUM VITAE.....</b>	<b>123</b>